Refine Your Search

  • Solutions

  • Therapeutic Areas

  • Resource Type

Certara Acquires Quantitative Systems Pharmacology Consultancy, XenologiQ

PRINCETON, NJ – Dec. 1, 2015 – Certara®, the global biosimulation technology-enabled drug development company, today announced that it has acquired XenologiQ, a UK-based quantitative systems pharmacology (QSP) consultancy. “This transaction strengthens Certara’s modeling and simulation capabilities, increases its leadership in mechanistic pharmacology, and supports the company’s precision medicine vision,” said Certara Chief Executive Officer […]

More Info

Can QSP Save Lives? Lessons from the Bial Trial Debacle

One of the biggest challenges for the pharmaceutical industry is the high rate of drug attrition in Phase 2 clinical trials, which wastes significant amounts of money and time. The major reasons for this attrition are that either candidate drugs do not show efficacy or have unexpected toxicity, in turn implying that we did not fully understand the complexity of the biology the candidate drugs were designed to modulate.

Speaker(s): Neil Benson
Solution: Biosimulation, Systems Pharmacology
Therapeutic Area: Central Nervous System
More Info

Can QSP Save Lives? Lessons from a Trial Debacle

The notion that volunteers could be harmed in a clinical trial is every drug developer’s worst nightmare. Earlier this year, the drug company, Bial, investigated inhibitors of the enzyme fatty acid amide hydrolase (FAAH) in clinical trials as a treatment for pain. Tragically, one person in the volunteer group died, and six patients were hospitalized. […]

Solution: Systems Pharmacology
Therapeutic Area: Central Nervous System
More Info
Learn More LinkedIn Twitter Facebook Email Subscribe to the Blog